证券代码：688238 证券简称：和元生物 公告编号：2025-063 和元生物技术（上海）股份有限公司 关于召开 2025 年三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 14 日(星期五)至 11 月 20 日(星期四)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 zhengquanbu@obiosh.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 和元生物技术（上海）股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日披露公司《2025 年三季度报告》，为便于广大投资者更全面深入地了解 公司 2025 年三季度经营成果、财务状况，公司计划于 2025 年 11 月 21 日(星期 五)下午 14:00-15:00 举行 2025 年三季度业绩说明会，就投资者关心的问题进行 交流。 一、说明会类型 本次业绩说明会以网络 ...

科创板上市公司独立董事候选人声明与承诺 本人计小青，已充分了解并同意由提名人和元生物技术（上海）股份有限公 司董事会提名为和元生物技术（上海）股份有限公司第四届董事会独立董事候选 人。本人公开声明，本人具备独立董事任职资格，保证不存在任何影响本人担任 和元生物技术（上海）股份有限公司独立董事独立性的关系，具体声明并承诺如 下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有五年以上法律、经济会计、财务、管理等履行独立董 事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （六）中共中央纪委、教育部、监察部《关于加强高等学校反腐倡廉建设的 意见》的相关规定（如适用）； （七）中国人民银行《股份制商业银行独立董事和外部监事制度指引》等的 相关规定（如适用）； （八）中国证监会《证券基金经营机构董事、监事、高级管理人员及从业人 员监督管理办法》等的相关规定（如适用）； （九）《银行业金融机构董事（理事）和高级管理人员任职资格管理办法》 《保险公司董事、监事和高级管理人员任职资格管理规定》《保险机构独立董事 管理办法》等的相关规 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-061 和元生物技术（上海）股份有限公司 关于公司董事辞职暨补选董事并调整董事会专门委 员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●和元生物技术（上海）股份有限公司（以下简称"公司"）董事会于近日 收到公司非独立董事王富杰先生提交的书面辞职报告。王富杰先生因个人身体健 康原因，经慎重考虑，申请辞去公司第四届董事会非独立董事职务，同时辞去第 四届董事会审计委员会委员职务。离任后，王富杰先生将不再担任公司任何职务。 ●公司董事会于近日收到公司独立董事吴丹枫女士提交的书面辞职报告。吴 丹枫女士因个人原因，申请辞去公司第四届董事会独立董事职务，同时辞去第四 届董事会审计委员会主任委员、薪酬与考核委员会委员职务。离任后，吴丹枫女 士将不再担任公司任何职务。 ●公司于 2025 年 10 月 24 日召开第四届董事会第四次会议，审议通过了《关 于补选第四届董事会非独立董事的议案》《关于变更第四届董事会独立董事的议 案》《关于调整第四届 ...

一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行政法规、规 章及其他规范性文件，具有五年以上法律、经济、会计、财务、管理等履行独立 董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训证明材料。 科创板上市公司独立董事提名人声明与承诺 提名人和元生物技术（上海）股份有限公司董事会，现提名计小青为和元生 物技术（上海）股份有限公司第四届董事会独立董事候选人，并已充分了解被提 名人职业、学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录 等情况。被提名人已书面同意出任和元生物技术（上海）股份有限公司第四届董 事会独立董事候选人（参见该独立董事候选人声明）。提名人认为，被提名人具 备独立董事任职资格，与和元生物技术（上海）股份有限公司之间不存在任何影 响其独立性的关系，具体声明并承诺如下： 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-062 和元生物技术（上海）股份有限公司 关于召开2025年第四次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第四次临时股东会 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相 结合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 11 月 13 日 14 点 00 分 召开地点：上海市临港新片区沧海路 3888 号 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 11 月 13 日 至2025 年 11 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 股东会召开日期：2025年 ...

Group 1 - The core viewpoint of the article highlights the financial performance of He Yuan Bio, indicating a decline in revenue and a significant net loss for the third quarter of 2025 [1] - He Yuan Bio reported revenue of approximately 180 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 1.91% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 162 million yuan, with basic earnings per share reflecting a loss of 0.254 yuan [1] Group 2 - As of the report, He Yuan Bio has a market capitalization of 4.9 billion yuan [2]

独立董事候选人计小青女士未持有公司股份。计小青女士与本公司的其他董 事、高级管理人员以及其他持有公司 5%以上股份的股东之间不存在关联关系。 计小青女士不存在《公司法》《公司章程》等法律、法规和规范性文件规定的不 得担任上市公司独立董事的情形，不属于失信被执行人，未受到过中国证监会及 其他有关部门的处罚以及证券交易所的惩戒和公开谴责，亦不存在因涉嫌犯罪被 司法机关立案侦查或因涉嫌违法违规被中国证监会立案稽查的情形，不存在被中 国证监会采取不得担任上市公司独立董事的市场禁入措施的情形，不存在被证券 交易场所公开认定为不适合担任上市公司独立董事的情形，具备《公司法》等相 关法律、法规和规范性文件和《公司章程》规定的任职资格。 综上，我们同意提名计小青女士为公司第四届董事会独立董事候选人，并同 意将该议案提交董事会审议。 和元生物技术（上海）股份有限公司 董事会提名委员会 2025 年 10 月 24 日 和元生物技术（上海）股份有限公司 董事会提名委员会关于独立董事候选人的审核意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》《上市公司独立董事管理办法》及《和元生物技术（上海 ...

Core Points - The Shanghai Municipal Federation of Industry and Commerce established a special committee for listed companies, consisting of 63 core executives from private listed companies, with Yang Guoping, Chairman and CEO of Dazhong Transportation Group, serving as the director [1] - The committee focuses on six key areas: strategic guidance, industrial collaboration, policy empowerment, financial support, standardized governance, and legal protection, aiming to enhance the quality of development of Shanghai's private economy [1] - As of now, there are 451 A-share listed companies in Shanghai, of which 254 are privately controlled, representing a crucial force in the private economy [1] - The first batch of committee members includes companies from integrated circuits, biomedicine, artificial intelligence, and green low-carbon sectors, with a total market capitalization exceeding half of the total market value of all private listed companies in Shanghai [1] - Shou Ziqi, Vice Chairman of the All-China Federation of Industry and Commerce and Chairman of the Shanghai Municipal Federation of Industry and Commerce, emphasized that private listed companies are the "leading geese" of Shanghai's private economy and the "vanguard" of technological innovation [1] Group 1 - The special committee aims to guide enterprises to align with national strategies, increase R&D investment, and promote digital and green transformation [1] - The committee will strengthen platform service functions, creating a "highway" for government-enterprise communication and a "hub" for resource matching and industrial coordination [1] - The committee intends to leverage leading enterprises to enhance and complement industrial chains, providing categorized services to optimize the capital market ecosystem [1] Group 2 - During a roundtable discussion, five committee member companies, including Dazhong Transportation, Spring Airlines, Geke Micro, Heyuan Bio, and Mercury Holdings, explored topics such as the transformation of technological innovation results, enhancing core competitiveness, and the integration of industrial chain formats [2]

Financial Performance - The company's operating revenue for the third quarter was ¥60,498,633.08, a decrease of 14.56% compared to the same period last year[3]. - The total profit for the period was -¥57,359,573.87, with a year-to-date total profit of -¥160,131,214.55[3]. - The net profit attributable to shareholders was -¥57,543,183.53 for the quarter, and -¥162,113,304.23 year-to-date[3]. - For the period from January to September 2025, the company achieved a total revenue of RMB 180.35 million, a decrease of 1.91% compared to the same period last year[13]. - Total operating revenue for the first three quarters of 2025 was CNY 180,353,622.06, a decrease of 1.38% compared to CNY 183,867,467.02 in the same period of 2024[22]. - Net loss for the first three quarters of 2025 was CNY 162,017,387.18, compared to a net loss of CNY 190,249,411.55 in 2024, indicating an improvement of approximately 14.8%[23]. - The company reported a net loss of CNY 137,813,466.84 for the first three quarters of 2025, slightly improved from a loss of CNY 139,868,068.54 in the same period of 2024[32]. - The total comprehensive income for the first three quarters of 2025 was CNY 3,466,939.99, contrasting with a total comprehensive loss of CNY 97,860,871.56 in the previous year[34]. Research and Development - Research and development expenses totaled ¥11,447,822.59, accounting for 18.92% of operating revenue, an increase of 4.70 percentage points year-on-year[4]. - Research and development expenses for the first three quarters of 2025 were CNY 34,661,199.52, down 11.5% from CNY 39,151,904.55 in 2024[23]. - Research and development expenses for the first three quarters of 2025 were CNY 7,103,505.30, down from CNY 9,531,235.41 in 2024, indicating a reduction of 25.5%[33]. - The company added 1 new invention patent and 6 domestic registered trademarks during the reporting period, with a total of 28 invention patents held[14]. Assets and Liabilities - Total assets at the end of the period were ¥2,116,971,711.57, a decrease of 7.34% from the end of the previous year[4]. - The equity attributable to shareholders decreased by 14.85% to ¥1,481,419,704.38 compared to the end of the previous year[4]. - The company's total assets decreased to CNY 2,116,971,711.57 in 2025 from CNY 2,284,740,741.02 in 2024, reflecting a decline of about 7.35%[20]. - Total liabilities increased to CNY 635,700,803.78 in 2025 from CNY 545,193,225.79 in 2024, representing an increase of approximately 16.58%[20]. - The total current assets as of September 30, 2025, were RMB 536.85 million, compared to RMB 690.43 million at the end of 2024[18]. - The total equity decreased to CNY 1,856,740,517.14 from CNY 1,951,617,896.66, indicating a decline in shareholder value[32]. Cash Flow - The company reported a net cash flow from operating activities of -¥110,580,815.39 year-to-date[3]. - The company's cash flow from operating activities for the first three quarters of 2025 was CNY 184,194,824.98, compared to CNY 166,602,196.16 in 2024, showing an increase of about 10.5%[26]. - The net cash flow from operating activities was CNY -110,580,815.39, showing a slight improvement from CNY -131,849,971.83 in the previous period[28]. - The net cash flow from operating activities for the first three quarters of 2025 was a negative CNY 140,060,624.34, an improvement from a negative CNY 244,030,174.45 in 2024[37]. - The net cash flow from investing activities was CNY -130,674,078.76, an improvement from CNY -232,360,860.25 in the previous period[28]. - Cash inflow from investment activities in the first three quarters of 2025 was CNY 240,358,095.33, compared to CNY 38,781,310.07 in the same period of 2024[37]. Business Operations - The decline in revenue was primarily due to a decrease in income from cell and gene therapy business[8]. - The revenue from cell and gene therapy CRO business was RMB 61.997 million, reflecting a growth of 2.81% year-over-year[13]. - The revenue from cell and gene therapy CDMO business was RMB 96.702 million, down 9.72% year-over-year, primarily due to the types of CDMO orders executed during the reporting period[13]. - Other main businesses, including research reagents and cell storage services, generated revenue of RMB 21.386 million, an increase of 55.99% year-over-year[13]. - The company secured over RMB 120 million in new CDMO orders during the reporting period[14]. - The company assisted clients in obtaining 16 IND application approvals in the US and China, including 1 FDA approval[14]. - As of September 30, 2025, the company had a total of 60 IND application approvals, with 14 from the FDA[14]. - The company's operating profit for the first three quarters of 2025 was CNY 3,144,311.43, a recovery from an operating loss of CNY 95,032,531.01 in the previous year[34]. - The cash outflow for purchasing goods and services in the first three quarters of 2025 was CNY 123,954,890.32, significantly higher than CNY 70,269,169.41 in 2024[37].

Core Insights - The medical services sector experienced a rise of 1.53% on October 21, with He Yuan Biological leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Medical Services Sector Performance - He Yuan Biological (688238) closed at 7.78, with an increase of 8.21% and a trading volume of 282,000 shares, amounting to 217 million yuan [1] - Other notable performers included Bei Rui Gene (000710) with a closing price of 13.22, up 3.77%, and Yao Kang Biological (688046) at 16.71, up 3.66% [1] - The sector saw a total net inflow of 250 million yuan from main funds, while retail investors experienced a net outflow of approximately 74 million yuan [2] Fund Flow Analysis - Major net inflows were observed in companies like Yao Ming Kang De (603259) with 353 million yuan, while retail investors showed significant outflows [3] - The top three companies by main fund inflow were Yao Ming Kang De (603259), Kang Long Hua Cheng (300759), and Hao Yuan Medical (688131) [3] - Retail investors showed a negative trend in several companies, indicating a cautious sentiment in the market [3]